OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

OXFORD BIOMEDICA AND ARIUS RESEARCH EXTEND COLLABORATION ON NOVEL CANCER TARGETS

Success of initial stage leads to further two-year partnership

Oxford BioMedica (LSE: OXB) and ARIUS Research Inc. (TSX-VE: ARI) announced today the first milestone and their decision to move into the next phase of their collaboration to discover and characterise novel cancer targets and downstream therapeutic products. Under the agreement, antigen targets and antibodies can be out-licensed to commercial partners or developed by one or both of the companies.

In the initial phase of the collaboration, which began on 25 July 2002, 50 functional anti-cancer antibodies from the ARIUS library were used by Oxford BioMedica to mine for novel targets. The decision to extend the collaboration comes from the successful identification of three targets that offer opportunities in a range of cancer diseases. The new collaboration will focus on one that is over-expressed in gastrointestinal and other cancers and is related to cancer metastasis.

The success of the initial phase is due to synergies between the two companies. ARIUS FunctionFIRST discovery platform starts with human tumour cells and selects for antibodies with direct anti-cancer effects. By not starting from a known target, the ARIUS platform offers opportunities to discover novel targets or the unique spots on a target that are important in triggering cancer cell death. Oxford BioMedica has a number of proprietary technologies from its gene discovery and immunotherapy programmes and has both the technical skills to develop products and the business development experience to market them.

ARIUS' President and CSO, Dr. David Young said: "Our ongoing relationship with Oxford BioMedica has the potential to deliver significant value as we move to commercialise these discoveries. Oxford BioMedica has been an excellent partner and has made an important contribution to developing these library candidates."

http://www.oxfordbiomedica.co.uk/news/2004-ob-19.htm

Thank you Janus - any view on why this does not merit RNS

There actually was an RNS Number:6130E but for some reason it wasnt picked up on all news services.

Thanks again - I am limited to picking up news from MoneyAM Stockwatch obviously on the stock I hold. How did you get hold of RNS 6130?

Normally I use
http://www.uk-wire.com/ but that wasnt picked up this morning on there. It was on ADVFN though http://www.advfn.com/p.php?pid=news&epic=OXB&cb=1099057225

:-)

Just as I said, an RNS would scupper my plan to buy some more at 16p.

i see one of the brokers, (can't remember which) has put a 45p target on these.

Panmure Gordon = Oxford Biomedica (OXB.L) (45p price target).

Isn't Panmure OXBs broker ???

Yes

Patrick Evershed's fund has a very large holding in this one and as he is AAA rated I followed him and bought a few. He said expect lots of positive news from OXB over the next few months---looks like it is starting to come through!!

UP again, will it break through 22p?

That could be interesting.

Looking at the 1 Year gragh I think a move upwards is on the cards. If it breaks the 22p mark then 25p is the next hurdle. Loads of products at phase 3 in their trials so im holding on for the long term.

Hearing rumours that GTAC has concerns re the safety of some lentiviruses that are used in Pro-Sarin. Anybody heard anything ?

Janus

Where did you hear / read these rumours from ????

A friend who is a doctor mentioned it, trying to find out more

More false rumours please, so that I can buy some more at a better price :-)

I have now seen a copy of a letter sent out by Professor Norman C Nevin GTAC Chairman, warning of concerns over the safety of some lentiviral gene therapy vectors. This states that reports have been received of the development of liver tumours in a pre-clinical study using lentiviral vectors. Most of the tumours occurred in a group of mice that had been treated in utero with a vector carrying the factor IX gene, although a small number of tumours were also observed in animals that had been treated neonatally or had received vectors carrying only marker genes.

The letter states that the number of mice involved is small and the wider implications are not yet clear. It also says that these observations do not appear to affect any current or previous UK trials so I have no idea how this affects OXB.

Not a problem, OXB have something for tumours aswell :)

lol well thats ok then :-)